株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のC型肝炎市場

Global Hepatitis C Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 311857
出版日 ページ情報 英文 104 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
世界のC型肝炎市場 Global Hepatitis C Market 2014-2018
出版日: 2014年09月03日 ページ情報: 英文 104 Pages
概要

C型肝炎はC型肝炎ウィルスへの感染が原因の病気であり、急性感染症もしくは慢性感染症を引き起こします。急性感染症を患う感染者の約80%が無症状性です。症状は、吐き気、暗色尿、発熱、食欲不振、灰色の顔色、腹痛および関節痛などの形で現れます。感染者の約20%が黄疸を発症します。急性感染者の約15-45%が感染から最初の6か月以内に自然に回復します。これは免疫システムを介してウィルスが体内から除去されるためです。ウィルスの除去に失敗した残り55-85%の感染者は、6か月以内に慢性C型肝炎を発症します。世界保健機構(WHO)によると、世界では1億3,000万〜1億5,000万人が慢性B型肝炎に苦しんでおり、毎年35万人〜50万人がC型肝炎関連の肝臓疾患で死亡しています。現在、C型肝炎を予防するワクチンはありませんが、さまざまな治療選択肢を利用することが出来ます。世界のC型肝炎市場は2013年〜2018年のCAGRで、19.20%の成長が見込まれています。

当レポートでは、世界のC型肝炎市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 疾患の概要

  • 感染伝播形態
  • 地域分布
  • スクリーニング
  • 治療
    • WHOのガイドライン
    • AASLDのガイドライン

第7章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第8章 慢性C型肝炎治療の主な上市薬

第9章 市場区分:MOA別

  • ウイルス特異物質
    • ポリメラーゼ阻害剤
    • プロテアーゼ阻害剤
  • 非特異物質
    • INF型薬剤
    • その他

第10章 地域区分

第11章 購入基準

第12章 市場成長促進要因

第13章 促進要因とその影響

第14章 市場課題

第15章 促進要因と課題の影響

第16章 市場動向

第17章 動向とその影響

第18章 ベンダー情勢

  • 競合シナリオ
  • 市場シェア分析
  • その他の有力ベンダー

第19章 主要ベンダー分析(事業概要、事業区分、事業戦略、SWOT分析など)

  • F. Hoffmann La Roche
  • Gilead
  • Johnson & Johnson
  • Merck
  • Vertex Pharmaceuticals

第20章 関連レポート

図表リスト

目次
Product Code: IRTNTR4050

About Hepatitis C

Hepatitis C is a liver disease caused by infection due to hepatitis C virus. Hepatitis C infection predominantly affects the liver; however, other parts of the body are also affected such as the brain and the digestive system. Hepatitis C virus is an RNA virus belonging to the family Flaviviridae and genus hepacivirus. It has a positive-sense, single-stranded RNA molecule enveloped by a lipid bilayer. Hepatitis C can lead to acute infection or chronic infection. Nearly 80 percent of the infected individuals suffering from acute infection are asymptomatic. Symptoms manifested in the rest include nausea, dark urine, fever, anorexia, gray-colored faces, abdominal pain, and joint pain. Nearly 20 percent of infected individuals develop jaundice, which is characterized by the yellowing of skin and eyes. Nearly 15-45 percent of acutely infected individuals recover from the infection spontaneously within the first six months of infection. This happens because the immune system mediated the clearance of the virus from the body. The remaining 55-85 percent of infected individuals who fail to clear the virus within six months develop chronic hepatitis C phase. Chronic infection can lead to mild-to-moderate symptoms or chronic symptoms such as liver fibrosis, liver cirrhosis, and hepatic cancer. The World Health Organization (WHO) estimates that globally, 130-150 million people suffer from chronic hepatitis B. It also reported that every year 350,000-500,000 infected individuals die because of hepatitis C-related hepatic disorders. Currently, there is no vaccine for the prevention of hepatitis C infection; however, various treatment options for hepatitis C infection are available.

TechNavio's analysts forecast the Global Hepatitis C market to grow at a CAGR of 19.20 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Hepatitis C market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through sales of various drugs administered to treat chronic hepatitis caused by genotype 1-6 of hepatitis C virus.

TechNavio's report, the Global Hepatitis C Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Hepatitis C market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • F. Hoffmann-La Roche
  • Gilead Sciences
  • Johnson & Johnson
  • Merck
  • Vertex Pharmaceuticals

Other Prominent Vendors

  • Abbvie
  • Achillion Pharmaceuticals
  • Bristol-Myers Squibb
  • Mitsubishi Tanabe Pharma
  • Novartis

Market Driver

  • Increase in Injection Drug Users

For a full, detailed list, view our report

Market Challenge

  • Side-effects of Current Therapy

For a full, detailed list, view our report

Market Trend

  • Emergence of Interferon-free Therapies

For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Mode of Infection Transmission
  • 06.2. Geographical Distribution
  • 06.3. Screening
  • 06.4. Treatment
    • 06.4.1. WHO Guidelines
    • 06.4.2. AASLD guidelines

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Key Marketed Drugs for Treatment of Chronic Hepatitis C

09. Market Segmentation by MOA

  • 09.1. Virus-specific Agents
    • 09.1.1. Polymerase Inhibitors
    • 09.1.2. Protease Inhibitors
  • 09.2. Non-specific Agents
    • 09.2.1. IFN-based Drugs
    • 09.2.2. Others

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2013
    • 18.2.1. Roche
    • 18.2.2. Merck
    • 18.2.3. Johnson and Johnson
    • 18.2.4. Vertex Pharmaceuticals
    • 18.2.5. Gilead
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. F. Hoffmann La Roche
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Business Segmentation by Revenue 2013
    • 19.1.4. Business Segmentation by Revenue 2012 and 2013
    • 19.1.5. Geographical Segmentation by Revenue 2013
    • 19.1.6. Business Strategy
    • 19.1.7. Recent Developments
    • 19.1.8. SWOT Analysis
  • 19.2. Gilead
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Geographical Segmentation by Revenue 2013
    • 19.2.4. Recent Developments
    • 19.2.5. SWOT Analysis
  • 19.3. Johnson & Johnson
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Business Segmentation by Revenue 2013
    • 19.3.4. Business Segmentation by Revenue 2012 and 2013
    • 19.3.5. Geographical Segmentation by Revenue 2013
    • 19.3.6. Business Strategy
    • 19.3.7. Recent Developments
    • 19.3.8. SWOT Analysis
  • 19.4. Merck
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Business Segmentation by Revenue 2013
    • 19.4.4. Business Segmentation by Revenue 2012 and 2013
    • 19.4.5. Sales by Geography
    • 19.4.6. Business Strategy
    • 19.4.7. Key Developments
    • 19.4.8. SWOT Analysis
  • 19.5. Vertex Pharmaceuticals
    • 19.5.1. Key Facts
    • 19.5.2. Business Overview
    • 19.5.3. Business Segmentation by Revenue 2013
    • 19.5.4. Business Segmentation by Revenue 2012 and 2013
    • 19.5.5. Geographical Segmentation by Revenue 2013
    • 19.5.6. Business Strategy
    • 19.5.7. Recent Developments
    • 19.5.8. SWOT Analysis

20. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Progression of Hepatitis C
  • Exhibit 3: Risk Factors for Hepatitis C Transmission
  • Exhibit 4: Prevalence Rates of Hepatitis C Across Different Geographies
  • Exhibit 5: Prevalence of Hepatitis C Genotypes in Tropical Latin America
  • Exhibit 6: Key Prevalence Data of Hepatitis C in East Asia and Pacific
  • Exhibit 7: Prevalence of Hepatitis C Genotypes in East Asia
  • Exhibit 8: Prevalence of Hepatitis C Genotypes in High Income Asia Pacific
  • Exhibit 9: Prevalence of Hepatitis C Genotypes in Australasia
  • Exhibit 10: Key Prevalence Data of Hepatitis C in Europe
  • Exhibit 11: Prevalence of Hepatitis C Genotypes in Eastern Europe
  • Exhibit 12: Prevalence of Hepatitis C Genotypes in Western Europe
  • Exhibit 13: Prevalence of Hepatitis C Genotypes in Central Europe
  • Exhibit 14: Key Prevalence Data of Hepatitis C in Latin America and Caribbean
  • Exhibit 15: Prevalence of Hepatitis C Genotypes in Tropical Latin America
  • Exhibit 16: Prevalence of Hepatitis C Genotypes in Andean Latin America
  • Exhibit 17: Prevalence of Hepatitis C Genotypes in Central Latin America
  • Exhibit 18: Prevalence of Hepatitis C Genotypes in South Latin America
  • Exhibit 19: Key Prevalence Data of Hepatitis C in Middle East and North Africa
  • Exhibit 20: Prevalence of Hepatitis C Genotypes in North Africa/Middle East
  • Exhibit 21: Key Prevalence Data of Hepatitis C in North America
  • Exhibit 22: Prevalence of Hepatitis C Genotypes in High Income Countries in North America
  • Exhibit 23: Key Prevalence Data of Hepatitis C in South Asia
  • Exhibit 24: Prevalence of Hepatitis C Genotypes in South Asia
  • Exhibit 25: Key Prevalence Data of Hepatitis C in Sub-Saharan Africa
  • Exhibit 26: Prevalence of Hepatitis C Genotypes in Central Sub-Saharan Africa
  • Exhibit 27: Prevalence of Hepatitis C Genotypes in East Sub-Saharan Africa
  • Exhibit 28: Prevalence of Hepatitis C Genotypes in South Sub-Saharan Africa
  • Exhibit 29: Prevalence of Hepatitis C Genotypes in West Sub-Saharan Africa
  • Exhibit 30: Screening Tests for Hepatitis C Infection
  • Exhibit 31: Global Hepatitis C Market 2013-2018 (US$ billion)
  • Exhibit 32: Global Hepatitis C Market Segmentation by MOA
  • Exhibit 33: Global Hepatitis C Market Segmentation by MOA 2013
  • Exhibit 34: Global Hepatitis C Market by Geographical Segmentation 2013
  • Exhibit 35: Geographical Segmentation of Pegasys Revenue 2013
  • Exhibit 36: Roche: Pipeline Candidates for Hepatitis C
  • Exhibit 37: Victrelis' Revenue 2011-2013 (US$ million)
  • Exhibit 38: Merck: Pipeline Candidates for Hepatitis C
  • Exhibit 39: Johnson & Johnson : Incivo's Revenue 2011-2013 (US$ million)
  • Exhibit 40: Olysio's Revenue 2014 (US$ million)
  • Exhibit 41: Vertex Pharmaceuticals: Incivek's Revenue 2011-2013 (US$ million)
  • Exhibit 42: Vertex: Pipeline Candidates for Hepatitis C
  • Exhibit 43: Gilead: Pipeline Candidates for Hepatitis C
  • Exhibit 44: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
  • Exhibit 45: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 46: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Pharmaceuticals Division)
  • Exhibit 47: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Diagnostics Division)
  • Exhibit 48: Gilead: Geographical Segmentation by Revenue 2013
  • Exhibit 49: Johnson & Johnson: Business Segmentation by Revenue 2013
  • Exhibit 50: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 51: Johnson & Johnson: Geographical Segmentation by Revenue 2013
  • Exhibit 52: Merck & Co. Inc.: Business Segmentation by Revenue 2013
  • Exhibit 53: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 54: Merck & Co. Inc.: Sales by Geography 2013
  • Exhibit 55: Vertex Pharmaceuticals: Business Segmentation by Revenue 2013
  • Exhibit 56: Vertex Pharmaceuticals: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Back to Top